Edarabid Injection
Edaravone
30mg+20ml
Intas Pharmaceuticals Ltd.
| Pack size | 1's |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 849.61 NPR |
Indications
Edarabid Injection is used for:
Amyotrophic lateral sclerosis (ALS), Neurological symptoms
Adult Dose
Intravenous
Adult: 30 mg of Edaravone IV two times a day.
The course of treatment should be less than 2 weeks.
IV infusion of Edaravone should be considered within 24 hours of onset of symptoms.
Child Dose
Renal Dose
Administration
Reconstituted with normal saline before administration.
Contra Indications
Hypersensitivity
Precautions
Caution with mild to moderate renal insufficiency, cardiac disorders, hepatic failure.
Pregnancy-Lactation
Interactions
Edaravone should not be used concomitantly with diazepam, phenytoin, cefotetan, piperacillin and cefazolin.
Adverse Effects
Side effects of Edaravone :
Acute renal failure, liver dysfunction, acute allergic reactions, disseminated intravascular coagulation, thrombocytopenia, and leukocytopenia, are occasionally observed by >5% of patients during edaravone treatment
Mechanism of Action
As a free radical scavenger, Edaravone lowers N- acetyl aspartate (NAA) and reduce cerebral blood flow into the cerebral infarct areas. The mechanism of Edaravone action reduces cerebral edema and cerebral infarction and lowers lipid-peroxidation induced neuronal death and subsequent oxidative stress of endothelial cells of the brain.
Note
Edarabid 30mg+20ml Injection manufactured by Intas Pharmaceuticals Ltd.. Its generic name is Edaravone. Edarabid is availble in Nepal.
Farmaco Nepal drug index information on Edarabid Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.